The study evaluated a blood test that can determine if healthy (‘asymptomatic’) individuals without a history of cancer have an increased risk of developing cancer within the next one year. This test can significantly minimize radiological or invasive screening in the majority individuals who do not have any increased risk. We have previously shown that circulating ensembles of tumor-associated cells (C-ETACs) are a systemic hallmark of cancer based on analysis of blood samples from 16,134 individuals including 10,625 asymptomatic individuals and 5,509 diagnosed cases of cancer. C-ETACs were ubiquitously (90%) detected across all cancer types and were rare (3.6%) among the asymptomatic population. Consequently, we hypothesized that asymptomatic individuals with detectable C-ETACs would have a definitively elevated risk of developing cancer as compared with individuals without C-ETACs. In the present manuscript we present 1-year follow-up data of the asymptomatic cohort which shows that C-ETAC positive individuals have a 230-fold (P < 0.00001) higher 1-year cancer risk as compared with individuals where C-ETACs were undetectable. Simultaneously, we also expanded the study to include 4,419 symptomatic individuals, suspected of cancer, prior to undergoing an invasive biopsy for diagnosis. C-ETACs were detected in 4,101 (92.8%) of these 4,419 cases where cancer was eventually confirmed. We conclude that detection of C-ETACs can identify patients at risk of cancer and can be reliably used to stratify asymptomatic individuals with an elevated 1-year risk of cancer. Prevention Relevance: The study evaluated a blood test that can determine if healthy (‘asymptomatic’) individuals without a history of cancer have an increased risk of developing cancer within the next one year. This test can significantly minimize radiological or invasive screening in the majority individuals who do not have any increased risk.

中文翻译：

---

标志性循环肿瘤相关细胞团意味着一年癌症风险高出 230 倍

该研究评估了一项血液测试，该测试可以确定没有癌症病史的健康（“无症状”）个体在未来一年内患癌症的风险是否增加。该测试可以显着减少大多数没有任何增加风险的个体的放射或侵入性筛查。我们之前已经表明，基于对 16,134 名个体（包括 10,625 名无症状个体和 5,509 名确诊癌症病例）的血液样本的分析，循环肿瘤相关细胞群 (C-ETAC) 是癌症的系统性标志。C-ETAC 在所有癌症类型中普遍存在（90%），在无症状人群中很少见（3.6%）。最后，我们假设与没有 C-ETAC 的个体相比，具有可检测到 C-ETAC 的无症状个体患癌症的风险明显升高。在本手稿中，我们提供了无症状队列的 1 年随访数据，显示 C-ETAC 阳性个体的 1 年癌症风险是 C-ETAC 阳性个体的 230 倍（P < 0.00001）。检测不到。同时，我们还将研究扩大到包括 4,419 名疑似癌症的有症状个体，然后进行侵入性活检以进行诊断。在这 4,419 例最终确诊为癌症的病例中，有 4,101 例（92.8%）检测到了 C-ETAC。我们得出结论，检测 C-ETAC 可以识别有癌症风险的患者，并且可以可靠地用于对 1 年癌症风险升高的无症状个体进行分层。预防相关性：该研究评估了一项血液测试，该测试可以确定没有癌症病史的健康（“无症状”）个体在未来一年内患癌症的风险是否增加。该测试可以显着减少大多数没有任何增加风险的个体的放射或侵入性筛查。